pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,499
stories
Jun 1, 26
STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes
stat
May 31, 26
STAT+: A standing ovation for RevMed, and caution for Akeso
stat
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 31, 26
#ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that good
endpoints
May 31, 26
#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
endpoints
May 31, 26
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
stat
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 31, 26
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
stat
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 31, 26
‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
biopharma dive
May 31, 26
#ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
endpoints
May 30, 26
#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say
endpoints
May 30, 26
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
stat
May 30, 26
STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
stat
May 30, 26
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
stat
May 29, 26
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
stat
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 29, 26
Bristol Myers unveils data for one of its next-gen blood cancer drugs
biopharma dive
May 29, 26
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
biopharma dive
May 29, 26
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
endpoints
May 29, 26
Replimune will again submit its melanoma drug for approval
endpoints
May 29, 26
Kenya court suspends U.S. plan for Ebola quarantine facility for Americans
stat
May 29, 26
Allogene CEO to step down; Agios drug fails key test
biopharma dive
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 29, 26
STAT+: Allogene CEO David Chang stepping down
stat
May 29, 26
FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs
fda press
May 29, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
May 29, 26
Pfizer, Innovent strike $10B cancer drug deal
biopharma dive
May 29, 26
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
endpoints
May 28, 26
STAT+: As Ebola outbreak in Central Africa grows, the U.S. turns itself into a fortress
stat
← prev
page 40 of 50
next →
